Latest in Cardiology from ACC.org

• Is ApoB an Appropriate Cost-Effective Marker For Lipid-Lowering Therapy?
  Apolipoprotein B (apoB) may be used as a cost-effective marker to improve population health and guide lipid-lowering therapy (LLT) in primary prevention, according to a computer simulation study published April 8 in JAMA.
• Higher CV Risk With Hematological Malignancies Varies By Subtype
  Patients and survivors of hematological malignancies face substantially elevated short- and long-term risk of cardiovascular disease compared with the general population – with risk varying significantly by malignancy subtype, according to a population-based cohort study published April 8 in JACC.
• Is PCI Superior to Medical Therapy For CTO in Patients With CCS?
  In patients with chronic coronary syndrome (CCS) with a single chronic total coronary occlusion (CTO) and no significant concomitant lesion, there was a greater improvement in quality of life (QoL) and symptom relief at 12 months, with no signal of excess harm, compared with optimal medical therapy (OMT)...
• ACC Asia 2026: Sex-Specific Differences in CVD Risk Factors in South Korea
  In adults with cardiovascular disease in South Korea, the rates of awareness and treatment of key cardiovascular risk factors were higher in women than in men, but they had lower rates of risk factor control, particularly for hypertension and hypercholesterolemia...
• STEP Analysis: BP Trajectories and CV Outcomes in Older Patients
  In older patients on intensive blood pressure (BP) treatment, the trajectory of BP control was an effective predictor of cardiovascular risk, with a rapid-stable pattern associated with the lowest risk and uncontrolled or unstable patterns associated with the highest risk, according to a post hoc analysis of data from the STEP trial published April 8 […]